AstraZeneca
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, AstraZeneca sits in the top decile of US sponsors by registered trial count (#20 of 15,742 sponsors by registered trial count).
AstraZeneca: 1,285 sponsored US clinical trials, 160 recruiting.
AstraZeneca sponsors 1,285 registered US clinical trials on ClinicalTrials.gov, 160 of them currently recruiting, and 883 completed. 484 of these trials are in Phase 3-4 (later-stage) and 720 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 24 trials.
Top-decile sponsor footprint
AstraZeneca ranks in the top decile of sponsors by registered trial count (#20 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
883 of 987 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,285 total, page 19 of 26
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension
NCT01104701
Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers
NCT01124760
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
NCT01107886
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects
NCT01135446
Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel
NCT01147588
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
NCT01145755
A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days
NCT01116258
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
NCT01116271
AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects
NCT01114152
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
NCT01112397
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
NCT01069926
Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin
NCT01096940
A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
NCT01094483
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
NCT01068717
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
NCT01042977
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
NCT01068756
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
NCT01078662
The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers
NCT00985933
A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days
NCT01064388
An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia
NCT01078675
A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels
NCT01069822
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
NCT01031680
Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus
NCT01082120
To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden
NCT00991419
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
NCT01068730
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
NCT01068743
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
NCT01049360
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
NCT01043185
Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers
NCT01037725
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
NCT00986531
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)
NCT01192139
Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)
NCT01044459
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR
NCT01192152
Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.
NCT01012375
A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687
NCT01046357
This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects
NCT01030224
AZD7268 Safety and Tolerability Study
NCT01020799
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
NCT01002807
This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses
NCT01027234
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
NCT00979134
AZD8683 Single Ascending Dose Study
NCT00979849
Dapagliflozin DPPIV Inhibitor add-on Study
NCT00984867
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
NCT01005251
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
NCT00995787
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
NCT00918138
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
NCT00960076
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
NCT00970268
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity
NCT00939094
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 444 |
| Phase 2 | 276 |
| Phase 3 | 437 |
| Phase 4 | 47 |
Therapeutic Areas
What is open in the AstraZeneca pipeline
160 recruiting of 1,285 indexed (12% open); 883 completed (69%).
Phase mix: 484 late (III/IV) vs 720 early (I/II) (balanced across stages).
Top condition: Non-Small Cell Lung Cancer (24 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AstraZeneca: open-pipeline peers nationwide
Peers matched on 1,285 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
AstraZeneca sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,285 trials (± recruiting share)
- University of Colorado, Denver · 1,283 trials · 21% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- Eli Lilly and Company · 1,341 trials · 9% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
Related
What to do with this AstraZeneca page
1,285 registered trials is a research-attention snapshot, not an endorsement of AstraZeneca or any single study.
- 160 of AstraZeneca's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition AstraZeneca studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AstraZeneca pipeline card: 1,285 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.